Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Jan;61(1):72–73. doi: 10.1038/bjc.1990.16

Alpha 1-antitrypsin and survival in hepatocellular carcinoma.

A Tzonou 1, L Sparos 1, V Kalapothaki 1, X Zavitsanos 1, A Rebelakos 1, D Trichopoulos 1
PMCID: PMC1971342  PMID: 2153397

Abstract

The association between serum levels of alpha 1-antitrypsin (alpha 1 AT) at the time of diagnosis and survival was studied in a group of 78 patients with confirmed hepatocellular carcinoma (HCC). All 78 patients were followed until the time of death, which occurred in all instances from HCC, with a median time of 6 months and a range of 1-117 months. Cox's proportional hazards model was utilised in the analysis controlling for sex, age, HBsAg status and logarithmically transformed values of alpha-fetoprotein (alpha-FP). Older patients and patients positive for HBsAg have suggestively higher fatality rates (0.05 less than P less than 0.10) whereas in these data sex and AFP levels were not important prognostic factors. Increased levels of serum at alpha 1AT at the time of diagnosis of HCC were statistically significantly (P less than 0.05) related with shorter survival, patients with higher serum alpha 1AT by 200 mg 100 ml-1 having an expected survival time shorter by about 25%.

Full text

PDF
72

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baskies A. M., Chretien P. B., Weiss J. F., Makuch R. W., Beveridge R. A., Catalona W. J., Spiegel H. E. Serum glycoproteins in cancer patients: first report of correlations with in vitro and in vivo parameters of cellular immunity. Cancer. 1980 Jun 15;45(12):3050–3060. doi: 10.1002/1097-0142(19800615)45:12<3050::aid-cncr2820451229>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  2. Buffone G. J., Stennis B. J., Schimbor C. M. Isoelectric focusing in agarose: classification of genetic variants of alpha 1-antitrypsin. Clin Chem. 1983 Feb;29(2):328–331. [PubMed] [Google Scholar]
  3. Chio L. F., Oon C. J. Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma. Cancer. 1979 Feb;43(2):596–604. doi: 10.1002/1097-0142(197902)43:2<596::aid-cncr2820430229>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  4. Cohen A. B. Unraveling the mysteries of alpha 1-antitrypsin deficiency. N Engl J Med. 1986 Mar 20;314(12):778–779. doi: 10.1056/NEJM198603203141211. [DOI] [PubMed] [Google Scholar]
  5. Cox D. W. Genetic variation of alpha 1-antitrypsin. Am J Hum Genet. 1978 Nov;30(6):660–662. [PMC free article] [PubMed] [Google Scholar]
  6. Dykes D. D., Miller S. A., Polesky H. F. Distribution of alpha 1-antitrypsin variants in a US white population. Hum Hered. 1984;34(5):308–310. doi: 10.1159/000153485. [DOI] [PubMed] [Google Scholar]
  7. Eriksson S. G. Liver disease in alpha 1-antitrypsin deficiency. Aspects of incidence and prognosis. Scand J Gastroenterol. 1985 Oct;20(8):907–911. doi: 10.3109/00365528509088844. [DOI] [PubMed] [Google Scholar]
  8. Eriksson S., Carlson J., Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986 Mar 20;314(12):736–739. doi: 10.1056/NEJM198603203141202. [DOI] [PubMed] [Google Scholar]
  9. Garver R. I., Jr, Mornex J. F., Nukiwa T., Brantly M., Courtney M., LeCocq J. P., Crystal R. G. Alpha 1-antitrypsin deficiency and emphysema caused by homozygous inheritance of non-expressing alpha 1-antitrypsin genes. N Engl J Med. 1986 Mar 20;314(12):762–766. doi: 10.1056/NEJM198603203141207. [DOI] [PubMed] [Google Scholar]
  10. Glasgow J. E., Bagdasarian A., Colman R. W. Functional alpha 1 protease inhibitor produced by a human hepatoma cell line. J Lab Clin Med. 1982 Jan;99(1):108–117. [PubMed] [Google Scholar]
  11. Govindarajan S., Ashcavai M., Peters R. L. alpha-1-Antitrypsin phenotypes in hepatocellular carcinoma. Hepatology. 1981 Nov-Dec;1(6):628–631. doi: 10.1002/hep.1840010611. [DOI] [PubMed] [Google Scholar]
  12. Harpel P. C. Protease inhibitors--a precarious balance. N Engl J Med. 1983 Sep 22;309(12):725–726. doi: 10.1056/NEJM198309223091210. [DOI] [PubMed] [Google Scholar]
  13. Ishikura H., Kirimoto K., Shamoto M., Miyamoto Y., Yamagiwa H., Itoh T., Aizawa M. Hepatoid adenocarcinomas of the stomach. An analysis of seven cases. Cancer. 1986 Jul 1;58(1):119–126. doi: 10.1002/1097-0142(19860701)58:1<119::aid-cncr2820580121>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  14. Kew M. C., Turnbull R., Prinsloo I. alpha1-Antitrypsin deficiency and hepatocellular cancer. Br J Cancer. 1978 Apr;37(4):635–638. doi: 10.1038/bjc.1978.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kühnl P., Spielmann W. PiT: a new allele in the alpha 1-antitrypsin system. Hum Genet. 1979;50(2):221–223. doi: 10.1007/BF00390245. [DOI] [PubMed] [Google Scholar]
  16. Marwick T. H., Cooney P. T., Kerlin P. Cirrhosis and hepatocellular carcinoma in a patient with heterozygous (MZ) alpha-1-antitrypsin deficiency. Pathology. 1985 Oct;17(4):649–652. doi: 10.3109/00313028509084770. [DOI] [PubMed] [Google Scholar]
  17. Matsuzaki S., Iwamura K., Itakura M., Kamiguchi H., Katsunuma T. A clinical evaluation of serum alpha-1-antichymotrypsin levels in liver disease and cancers. Gastroenterol Jpn. 1981 Dec;16(6):582–591. doi: 10.1007/BF02813793. [DOI] [PubMed] [Google Scholar]
  18. Morse J. O. alpha1-antitrypsin deficiency (first of two parts). N Engl J Med. 1978 Nov 9;299(19):1045–1048. doi: 10.1056/NEJM197811092991905. [DOI] [PubMed] [Google Scholar]
  19. Schneider M., Pott G., Gerlach U. Alpha-1-Antitrypsin-Mangel. Eine Ubersicht unter besonderer Berücksichtigung der Bedeutung des heterozygoten Mangels. Klin Wochenschr. 1986 Mar 3;64(5):197–205. doi: 10.1007/BF01711647. [DOI] [PubMed] [Google Scholar]
  20. Sparos L., Tountas Y., Chapuis-Cellier C., Theodoropoulos G., Trichopoulos D. Alpha 1-antitrypsin levels and phenotypes and hepatitis B serology in liver cancer. Br J Cancer. 1984 May;49(5):567–570. doi: 10.1038/bjc.1984.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Thompson D. K., Haddow J. E., Smith D. E., Ritchie R. F. Elevated serum acute phase protein levels as predictors of disseminated breast cancer. Cancer. 1983 Jun 1;51(11):2100–2104. doi: 10.1002/1097-0142(19830601)51:11<2100::aid-cncr2820511124>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  22. Trichopoulos D., Sizaret P., Tabor E., Gerety R. J., Martel N., Munoz N., Theodoropoulos G. Alphafetoprotein levels of liver cancer patients and controls in a European population. Cancer. 1980 Aug 15;46(4):736–740. doi: 10.1002/1097-0142(19800815)46:4<736::aid-cncr2820460417>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  23. Trichopoulos D., Tabor E., Gerety R. J., Xirouchaki E., Sparros L., Munoz N., Linsell C. A. Hepatitis B and primary hepatocellular carcinoma in a European population. Lancet. 1978 Dec 9;2(8102):1217–1219. doi: 10.1016/s0140-6736(78)92097-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES